Advanced Biomedical Technologies Inc. (ABMT) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
200 PARK AVENUE, SUITE 1700 NEW YORK, NY 10166 |
| State of Incorp. | |
| Fiscal Year End | October 31 |
| Industry (SIC) | 3842 - Orthopedic, Prosthetic, and Surgical Appliances and Supplies (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 7/31/2021 MRQ | 10/31/2020 | 10/31/2019 | 10/31/2018 | 10/31/2017 | 10/31/2016 | 10/31/2015 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 202 | 6 | 7 | 7 | 7 | 38 | |||
| Cash and cash equivalent | 202 | 6 | 7 | 7 | 7 | 38 | |||
| Inventory, net of allowances, customer advances and progress billings | 100 | 64 | 3 | ||||||
| Inventory | 100 | 64 | 3 | ||||||
| Prepaid expense | 17 | 20 | 18 | ||||||
| Other undisclosed current assets | 29 | 50 | 33 | ||||||
| Total current assets: | 331 | 119 | 40 | 25 | 27 | 59 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 33 | ✕ | ✕ | ✕ | ✕ | ||||
| Property, plant and equipment | 105 | 99 | 103 | 61 | 72 | 107 | |||
| Other undisclosed noncurrent assets | 1 | ||||||||
| Total noncurrent assets: | 138 | 99 | 103 | 61 | 74 | 107 | |||
| TOTAL ASSETS: | 469 | 219 | 142 | 85 | 101 | 166 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Other liabilities | 443 | 409 | 338 | 97 | |||||
| Due to related parties | 4,706 | 4,917 | 4,326 | 3,767 | 3,084 | 3,528 | |||
| Other undisclosed current liabilities | 3,158 | 1,780 | 993 | 904 | 1,042 | 1,002 | |||
| Total current liabilities: | 7,864 | 6,697 | 5,761 | 5,080 | 4,463 | 4,627 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation: | 7 | ||||||||
| Operating lease, liability | 7 | ✕ | ✕ | ✕ | ✕ | ||||
| Total noncurrent liabilities: | 14 | ||||||||
| Total liabilities: | 7,878 | 6,697 | 5,761 | 5,080 | 4,463 | 4,627 | |||
| Commitments and contingencies | 1 | ||||||||
| Equity | |||||||||
| Equity, attributable to parent, including: | (7,402) | (6,478) | (5,619) | (4,995) | (4,362) | (4,461) | |||
| Common stock | 1 | 1 | 1 | 1 | 1 | 1 | |||
| Additional paid in capital | 2,824 | 2,768 | 2,740 | 2,674 | 2,521 | 1,949 | |||
| Accumulated other comprehensive income (loss) | 21 | 334 | 273 | 10 | 104 | (148) | |||
| Accumulated deficit | (10,256) | (9,581) | (8,633) | (7,679) | (6,988) | (6,263) | |||
| Other undisclosed equity, attributable to parent | 8 | ||||||||
| Total equity: | (7,402) | (6,478) | (5,619) | (4,995) | (4,362) | (4,461) | |||
| Other undisclosed liabilities and equity | (7) | (1) | |||||||
| TOTAL LIABILITIES AND EQUITY: | 469 | 219 | 142 | 85 | 101 | 166 | |||
Income Statement (P&L) ($ in thousands)
| 7/31/2021 TTM | 10/31/2020 | 10/31/2019 | 10/31/2018 | 10/31/2017 | 10/31/2016 | 10/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 124 | 12 | ||||||
| Revenue from related parties | 111 | ✕ | ✕ | ✕ | ||||
| Cost of revenue | (52) | (8) | ||||||
| Gross profit: | 72 | 4 | ||||||
| Operating expenses | (518) | (609) | (634) | (404) | (461) | (605) | ||
| Other operating expense, net | (258) | |||||||
| Other undisclosed operating income | 258 | |||||||
| Operating loss: | (447) | (605) | (634) | (404) | (461) | (605) | ||
| Nonoperating expense | (225) | (344) | (19) | (30) | (14) | (16) | ||
| Other nonoperating expense | (22) | (18) | (19) | (30) | (14) | (16) | ||
| Interest and debt expense | (14) | (13) | (14) | (16) | (249) | (241) | ||
| Loss from continuing operations before equity method investments, income taxes: | (686) | (962) | (667) | (449) | (725) | (863) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 14 | 13 | (287) | (242) | ||||
| Loss from continuing operations: | (672) | (949) | (953) | (692) | (725) | (863) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (672) | (949) | (953) | (692) | (725) | (863) | |
| Net loss available to common stockholders, diluted: | (672) | (949) | (953) | (692) | (725) | (863) | ||
Comprehensive Income ($ in thousands)
| 7/31/2021 TTM | 10/31/2020 | 10/31/2019 | 10/31/2018 | 10/31/2017 | 10/31/2016 | 10/31/2015 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (672) | (949) | (953) | (692) | (725) | (863) | ||
| Other comprehensive income (loss) | (313) | 62 | 263 | (94) | 252 | 119 | ||
| Comprehensive loss, net of tax, attributable to parent: | (985) | (887) | (691) | (786) | (472) | (744) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.